Top Markets
Coin of the day
Oscotec Inc. Oscotec Inc.

Oscotec Inc.

039200
株式のランク #9790
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and... Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Phase IIa clinical trials for the treatment of both rheumatoid arthritis and immune thrombocytopenia. Another key asset is an FLT3 inhibitor, undergoing Phase I clinical evaluation for acute myeloid leukemia. The company is also developing an EGFR double mutation inhibitor aimed at non-small cell lung cancer, and an Anti-Tau antibody in the preclinical stage for Alzheimer's disease. Beyond its pharmaceutical endeavors, Oscotec Inc. diversifies its offerings with a range of dental health products, such as bone graft materials like InduCera, BioCera-F, and SynCeraII, alongside membranes including LysoGide and CollaGuide. Additionally, it markets functional ingredients designed to address specific health concerns, such as OPB for osteoporosis, AIF for arthritis, SGA for enhancing bone growth, and PRF-K for periodontal conditions. Established in 1988, the company, originally known as Oscotec Co., Ltd, adopted its current name, Oscotec Inc., in June 1999. It is headquartered in Seongnam, South Korea.
株価
$24.76
最終同期: 2026-08-28
時価総額
$947.10M
変化(1日)
2.14%
変化(1年)
-6.44%
KR
取引 Oscotec Inc. (039200)

カテゴリー

Oscotec Inc.(039200)の収益
Aug 2026 時点の収益 TTM: 0
Oscotec Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Oscotec Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$79.67B -
US
$97.93B -
US
$64.39B -
US
$77.52B -
CH
$66.40B -
US